Trial
NCT04612712
A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Collaborators
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Condition
Advanced Gastrointestinal Tumors
Intervention
Donafenib Tosilate Tablets
Why stopped
Due to R\&D strategy adjustments; no safety issues involved.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-01